TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up
Teva stock jumps after third-quarter earnings and revenues top estimates, driven by robust Austedo sales as well as U.S. generics growth.
Teva Pharmaceuticals CEO on earnings beat: Our shift to biopharma is working
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's driving growth, and much more.
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 Earnings
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Ethic Inc.
Ethic Inc. reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 7.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,490 shares of the company's stock after selling 1,399 shares during the quarter. Ethic Inc.'s holdings in
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside
Teva Pharmaceutical Industries Limited is regaining investor interest as restructuring efforts drive margin improvements and unlock pipeline potential. Turnaround: company is changing to a more profitable company. Duvakitug and the company's other pipelines have significant future potential.
Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 8:30 AM EDT Company Participants Richard Francis - President, CEO & Director Conference Call Participants Thibault Boutherin - Morgan Stanley, Research Division Presentation Thibault Boutherin Equity Analyst Okay. So I think we'll start.
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Teva is transforming, with management delivering on profit growth, specialty drug expansion, and improving its balance sheet—yet the stock remains undervalued. Specialty products like AUSTEDO and UZEDY are driving margin improvement, while partnerships and cost-cutting support a credible turnaround. Despite lingering legal and debt risks, Teva's low valuation offers a favorable risk/reward for patient investors willing to look past old headlines.
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Christopher J. Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Eliyahu Sharon Kalif - Executive VP & CFO Eric A.
